Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Phenylethylamine in neuropsychiatric disorders.

M E Wolf, A D Mosnaim

General Pharmacology

|January 1, 1983

Summary

Phenylethylamine (PEA), the body's natural amphetamine, is implicated in neuropsychiatric disorders. Altered PEA levels are linked to conditions like phenylketonuria, depression, schizophrenia, and Parkinson's disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Risk scores for transient ischemic attack.

Frontiers of neurology and neuroscience·2013

Same author

Antithrombotic therapy in transient ischemic attack patients.

Frontiers of neurology and neuroscience·2013

Same author

The ASCOD phenotyping of ischemic stroke (Updated ASCO Phenotyping).

Cerebrovascular diseases (Basel, Switzerland)·2013

Same author

Continuous magnetic resonance perfusion imaging acquisition during systemic thrombolysis in acute stroke.

Cerebrovascular diseases (Basel, Switzerland)·2013

Same author

Characterization of patients with recurrent ischaemic stroke using the ASCO classification.

European journal of neurology·2013

Same author

Multiple subcortical acute ischemic lesions reflect small vessel disease rather than cardiogenic embolism.

Journal of neurology·2012

Area of Science:

Neuroscience
Biochemistry
Psychiatry

Background:

Phenylethylamine (PEA) is an endogenous neuroamine.
It is conceptualized as the body's natural amphetamine.
PEA may play a role in the etiology of neuropsychiatric disorders.

Purpose of the Study:

To explore the role of phenylethylamine (PEA) in the pathophysiology of various neuropsychiatric conditions.
To investigate the relationship between PEA levels and disorders such as phenylketonuria, depression, schizophrenia, and Parkinson's disease.

Main Methods:

The study reviews existing literature on PEA levels in different patient populations and animal models.
Analysis of urinary PEA excretion in patients with depression, schizophrenia, and Parkinson's disease.
Examination of brain PEA levels in animal models of depression and Parkinson's disease.

Main Results:

Increased PEA turnover is associated with phenylketonuria.
Depressed patients show decreased urinary PEA excretion, while chronic paranoid schizophrenic patients exhibit increased excretion.
Parkinsonian patients demonstrate decreased urinary PEA excretion.
Animal studies show that drugs affecting depression and Parkinson's disease alter brain PEA levels.

Conclusions:

Phenylethylamine (PEA) is implicated in the pathophysiology of phenylketonuria.
Altered PEA levels are associated with depression, schizophrenia, and Parkinson's disease.
PEA may also play a role in migraine headache and aggression.

Related Experiment Videos